DK2421541T3 - : NEW USE - Google Patents
: NEW USE Download PDFInfo
- Publication number
- DK2421541T3 DK2421541T3 DK10714956.9T DK10714956T DK2421541T3 DK 2421541 T3 DK2421541 T3 DK 2421541T3 DK 10714956 T DK10714956 T DK 10714956T DK 2421541 T3 DK2421541 T3 DK 2421541T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- gal
- gos
- tnf
- mip
- Prior art date
Links
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 41
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 41
- DLRVVLDZNNYCBX-JZSVMVJISA-N beta-D-Galp-(1->6)-D-Galp Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-JZSVMVJISA-N 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 150000004043 trisaccharides Chemical class 0.000 claims description 4
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 53
- 102000004890 Interleukin-8 Human genes 0.000 description 45
- 108090001007 Interleukin-8 Proteins 0.000 description 45
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 39
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 30
- 230000028327 secretion Effects 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 102100035100 Transcription factor p65 Human genes 0.000 description 7
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010040721 Flagellin Proteins 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000004890 epithelial barrier function Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 101710193592 ORF3a protein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001032 ion-exclusion chromatography Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0906983.2A GB0906983D0 (en) | 2009-04-23 | 2009-04-23 | Novel use |
| GBGB0920784.6A GB0920784D0 (en) | 2009-04-23 | 2009-11-27 | Novel use |
| PCT/GB2010/050659 WO2010122344A1 (en) | 2009-04-23 | 2010-04-23 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2421541T3 true DK2421541T3 (en) | 2018-09-24 |
Family
ID=40774842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10714956.9T DK2421541T3 (en) | 2009-04-23 | 2010-04-23 | : NEW USE |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20120058972A1 (https=) |
| EP (1) | EP2421541B1 (https=) |
| JP (1) | JP2012524770A (https=) |
| KR (1) | KR20110138416A (https=) |
| CN (1) | CN102427818A (https=) |
| AU (1) | AU2010240642B2 (https=) |
| BR (1) | BRPI1015091A2 (https=) |
| CA (1) | CA2759442C (https=) |
| CY (1) | CY1120597T1 (https=) |
| DK (1) | DK2421541T3 (https=) |
| ES (1) | ES2688786T3 (https=) |
| GB (3) | GB0906983D0 (https=) |
| HU (1) | HUE040451T2 (https=) |
| IL (1) | IL215855A0 (https=) |
| MX (1) | MX341308B (https=) |
| MY (1) | MY151104A (https=) |
| NZ (1) | NZ595969A (https=) |
| PL (1) | PL2421541T3 (https=) |
| PT (1) | PT2421541T (https=) |
| RU (1) | RU2530567C2 (https=) |
| SG (1) | SG175313A1 (https=) |
| TR (1) | TR201810868T4 (https=) |
| UA (1) | UA106491C2 (https=) |
| WO (1) | WO2010122344A1 (https=) |
| ZA (1) | ZA201107821B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2492559B (en) * | 2011-07-05 | 2018-07-25 | Clasado Inc | Composition and method for preventing or reducing the risk of developing a syndrome |
| DK2734210T3 (en) | 2011-07-22 | 2018-01-22 | Abbott Lab | GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL |
| CN103716787B (zh) | 2012-09-29 | 2020-06-23 | 北京三星通信技术研究有限公司 | 一种支持对家用基站进行验证的方法 |
| CN107771083A (zh) * | 2015-04-23 | 2018-03-06 | 卡莱多生物科技有限公司 | 聚糖治疗剂和治疗方法 |
| CN107158011A (zh) * | 2017-05-25 | 2017-09-15 | 浙江大学 | 低聚半乳糖在制备治疗肠道疾病的药物中的用途 |
| US12508273B2 (en) | 2019-05-15 | 2025-12-30 | N.V. Nutricia | Beta-1,3′-galactosyllactose for the treatment of gut barrier function diseases |
| US20240277739A1 (en) * | 2021-07-01 | 2024-08-22 | N.V. Nutricia | Nutritonal compositions for gut barrier function |
| KR102453998B1 (ko) * | 2022-01-07 | 2022-10-14 | (주)네오크레마 | 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물 |
| GB2619977A (en) * | 2022-06-24 | 2023-12-27 | Clasado Res Services Limited | Compositions and uses thereof |
| GB2623336A (en) * | 2022-10-12 | 2024-04-17 | Clasado Res Services Limited | Compositions and uses thereof |
| GB2623335A (en) * | 2022-10-12 | 2024-04-17 | Clasado Res Services Limited | Compositions and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| GB0315266D0 (en) * | 2003-06-30 | 2003-08-06 | Clasado Inc | Novel galactooligosaccharide composition and the preparation thereof |
| ATE360682T1 (de) * | 2003-06-30 | 2007-05-15 | Clasado Inc | Neue galactooligosaccharidzusammensetzung und herstellung davon |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| EP1887017A1 (en) * | 2006-08-09 | 2008-02-13 | Friesland Brands B.V. | Prebiotic carbohydrate |
| GB0809921D0 (en) | 2008-05-30 | 2008-07-09 | Clasado Inc | Product and process therefor |
-
2009
- 2009-04-23 GB GBGB0906983.2A patent/GB0906983D0/en not_active Ceased
- 2009-11-27 GB GBGB0920784.6A patent/GB0920784D0/en not_active Ceased
-
2010
- 2010-04-23 CN CN2010800180409A patent/CN102427818A/zh active Pending
- 2010-04-23 AU AU2010240642A patent/AU2010240642B2/en active Active
- 2010-04-23 TR TR2018/10868T patent/TR201810868T4/tr unknown
- 2010-04-23 MY MYPI2011004912 patent/MY151104A/en unknown
- 2010-04-23 CA CA2759442A patent/CA2759442C/en active Active
- 2010-04-23 GB GB1120030.0A patent/GB2482817B/en active Active
- 2010-04-23 RU RU2011147390/15A patent/RU2530567C2/ru not_active IP Right Cessation
- 2010-04-23 BR BRPI1015091A patent/BRPI1015091A2/pt not_active Application Discontinuation
- 2010-04-23 US US13/265,532 patent/US20120058972A1/en not_active Abandoned
- 2010-04-23 JP JP2012506581A patent/JP2012524770A/ja active Pending
- 2010-04-23 NZ NZ595969A patent/NZ595969A/xx not_active IP Right Cessation
- 2010-04-23 KR KR1020117027762A patent/KR20110138416A/ko not_active Ceased
- 2010-04-23 PT PT10714956T patent/PT2421541T/pt unknown
- 2010-04-23 ES ES10714956.9T patent/ES2688786T3/es active Active
- 2010-04-23 WO PCT/GB2010/050659 patent/WO2010122344A1/en not_active Ceased
- 2010-04-23 SG SG2011077443A patent/SG175313A1/en unknown
- 2010-04-23 MX MX2011011159A patent/MX341308B/es active IP Right Grant
- 2010-04-23 PL PL10714956T patent/PL2421541T3/pl unknown
- 2010-04-23 HU HUE10714956A patent/HUE040451T2/hu unknown
- 2010-04-23 UA UAA201113760A patent/UA106491C2/uk unknown
- 2010-04-23 DK DK10714956.9T patent/DK2421541T3/en active
- 2010-04-23 EP EP10714956.9A patent/EP2421541B1/en not_active Revoked
-
2011
- 2011-10-23 IL IL215855A patent/IL215855A0/en unknown
- 2011-10-25 ZA ZA2011/07821A patent/ZA201107821B/en unknown
-
2018
- 2018-08-13 CY CY181100857T patent/CY1120597T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2421541T (pt) | 2018-10-15 |
| RU2011147390A (ru) | 2013-05-27 |
| SG175313A1 (en) | 2011-11-28 |
| MX2011011159A (es) | 2011-11-07 |
| CN102427818A (zh) | 2012-04-25 |
| IL215855A0 (en) | 2012-01-31 |
| WO2010122344A1 (en) | 2010-10-28 |
| GB2482817B (en) | 2014-02-26 |
| MX341308B (es) | 2016-08-12 |
| CY1120597T1 (el) | 2019-12-11 |
| CA2759442A1 (en) | 2010-10-28 |
| NZ595969A (en) | 2013-03-28 |
| EP2421541B1 (en) | 2018-07-11 |
| JP2012524770A (ja) | 2012-10-18 |
| BRPI1015091A2 (pt) | 2016-04-26 |
| TR201810868T4 (tr) | 2018-08-27 |
| AU2010240642A1 (en) | 2011-11-10 |
| KR20110138416A (ko) | 2011-12-27 |
| ZA201107821B (en) | 2012-07-25 |
| GB201120030D0 (en) | 2012-01-04 |
| US20120058972A1 (en) | 2012-03-08 |
| AU2010240642B2 (en) | 2013-03-14 |
| HUE040451T2 (hu) | 2019-03-28 |
| MY151104A (en) | 2014-04-15 |
| EP2421541A1 (en) | 2012-02-29 |
| CA2759442C (en) | 2016-01-19 |
| GB2482817A (en) | 2012-02-15 |
| GB0906983D0 (en) | 2009-06-03 |
| RU2530567C2 (ru) | 2014-10-10 |
| UA106491C2 (uk) | 2014-09-10 |
| GB0920784D0 (en) | 2010-01-13 |
| ES2688786T3 (es) | 2018-11-06 |
| PL2421541T3 (pl) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2421541T3 (en) | : NEW USE | |
| US20110082102A1 (en) | Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation | |
| Nijman et al. | Characterization and quantification of oligosaccharides in human milk and infant formula | |
| Newburg et al. | Human milk oligosaccharides and synthetic galactosyloligosaccharides contain 3′-, 4-, and 6′-galactosyllactose and attenuate inflammation in human T84, NCM-460, and H4 cells and intestinal tissue ex vivo | |
| Craft et al. | Interrogation of human milk oligosaccharide fucosylation patterns for antimicrobial and antibiofilm trends in group B Streptococcus | |
| Xu et al. | Orally administered ginkgolide C attenuates DSS-induced colitis by maintaining gut barrier integrity, inhibiting inflammatory responses, and regulating intestinal flora | |
| A. Parnell et al. | Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome | |
| AU2015262214B2 (en) | Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria | |
| Logtenberg et al. | Touching the high complexity of prebiotic vivinal galacto-oligosaccharides using porous graphitic carbon ultra-high-performance liquid chromatography coupled to mass spectrometry | |
| US8425930B2 (en) | Prebiotic oligosaccharides | |
| US20240309408A1 (en) | Methods of Use of Oligosaccharide Compositions for Modulating Microbiota and their Metabolic Products, and as Therapeutics for Health Applications | |
| Fernández Fernández et al. | Healthy effects of prebiotics and their metabolites against intestinal diseases and colorectal cancer | |
| Wu et al. | Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α–lowering properties through modulating gut microbiota in db/db mice | |
| Ceresola et al. | Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation. | |
| Diez-Municio et al. | Efficient synthesis and characterization of lactulosucrose by Leuconostoc mesenteroides B-512F dextransucrase | |
| Ambrogi et al. | Bifidobacterial β-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments | |
| Kim et al. | Supplementation with the probiotic strains Bifidobacterium longum and Lactiplantibacillus rhamnosus alleviates glucose intolerance by restoring the IL-22 response and pancreatic beta cell dysfunction in type 2 diabetic mice | |
| Sato et al. | An effectiveness study of hyaluronic acid [Hyabest®(J)] in the treatment of osteoarthritis of the knee on the patients in the United States | |
| Macfarlane et al. | Food and the large intestine | |
| Ambrogi et al. | Bifidobacterial ß-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments | |
| US20140212494A1 (en) | Methods of Improving Digestive Health | |
| Manchanayake | The Impact of Gut Microbiota on Host Obesity. J Gastrointest Dig Syst 9: 591. doi: 10.4172/2161-069X. 1000591 Page 2 of 8 J Gastrointest Dig Syst, an open access journal ISSN: 2161-069X Volume 9• Issue 1• 1000591 | |
| Ambrogi et al. | β-Galactosidase-Mediated Production of Galacto-Oligosaccharides: Structural and Preliminary Functional Assessments |